CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference, occurring May 23-26, 2022.
The presentation will be available for on-demand viewing beginning May 24, 2022 at 7:00AM EST via the virtual conference link, and will be archived for 90 days.
Exicure will be taking 1x1 investor meetings with registered conference attendees.
Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com.